Blocking rhinoviral adhesion molecule (ICAM-1): potential to prevent COPD exacerbations.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Pelargonium sidoides radix extract EPs 7630 reduces rhinovirus infection through modulation of viral binding proteins on human bronchial epithelial cells.PloS one · 2019
   Trial
2. Proposed mechanisms of action of herbal drugs and their biologically active constituents in the treatment of coughs: an overview.PeerJ · 2023
   Review
3. Targeting intercellular adhesion molecule-1 (ICAM-1) to reduce rhinovirus-induced acute exacerbations in chronic respiratory diseases.Inflammopharmacology · 2022
   Review
4. Molecular Characteristics and Treatment of Endothelial Dysfunction in Patients with COPD: A Review Article.International journal of molecular sciences · 2019
   Review

Corrections and comments

• Comment on
  Colds as predictors of the onset and severity of COPD exacerbations.2017

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as